STAT

You’ve swum with one, stepped on one, maybe swallowed one. This unsung invertebrate could teach us about aging

Behold the rotifer, an unsung invertebrate that could help untangle the biology of aging.

WOODS HOLE, Mass. — In case you were wondering, Kristin Gribble is not a basher of fruit flies or roundworms. She wants to be clear: She bears no ill will toward those invertebrates so often studied that they’ve become scientific celebrities, recognizable by their truncated Latin names. She knows that Drosophila and C. elegans are powerful tools. She understands the allure of experimenting on creatures we know better than we know ourselves.

As an ecologist, she also thinks we might come to know ourselves a little better — and perhaps, stave off certain indignities of old age — by scrutinizing less famous spineless creatures in the lab. She’s staked her career on a particularly obscure one, and hopes others might do the same. Three to five times a year, she makes a point of mingling with the telomere-researchers and cell-rejuvenators and longevity-hounds who populate scientific conferences on aging. Like everyone else, she’s there to give papers and exchange ideas. But she’s also on a mission: to preach the gospel of rotifers.

“I feel like a

You’re reading a preview, subscribe to read more.

More from STAT

STAT2 min read
STAT+: Pharmalittle: We’re Reading About An Amgen Obesity Drug, A Senate Bill On Shortages, And More
Amgen will no longer develop an early-stage obesity pill, and will instead focus on a more advanced injectable candidate to compete with Wegovy and Zepbound.
STAT2 min read
STAT+: Pharmalittle: We’re Reading About AstraZeneca CEO Pay, Alternatives To WuXi And More
And so, another working week will soon draw to a close. Not a moment too soon, yes? This is, you may recall, our treasured signal to daydream about weekend plans.…
STAT2 min read
STAT+: Pharmalittle: We’re Reading About FTC Fighting ‘Junk’ Patents, Pfizer Direct-to-consumer Plans, And More
The FTC expanded its campaign against pharmaceutical companies for filing what it calls “junk” patent listings for 20 different brand-name treatments.

Related Books & Audiobooks